country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

76 Results for "

BH 3

" in MedChemExpress (MCE) Product Catalog:

Products (76)

Sort by :

Categories

By Targets

Species:

Tags:

Sources:

Hosts:

Reactivities:

Applications:

Conjugations:

Clonalities:

Modifications:

Products

166

Navitoclax dihydrochloride

166 Publications Verification

Cat. No.: HY-10087A1

CAS No.: 1093851-28-5

Synonyms: ABT-263 dihydrochloride

Target:

Bcl-2 Family Apoptosis Survivin TGF-β Receptor

Research Areas:

Cardiovascular Disease Cancer

Navitoclax dihydrochloride (ABT-263 dihydrochloride) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a K_i value of <1 nM for each target. Navitoclax dihydrochloride triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax dihydrochloride alleviates fibrosis and induces thrombocytopenia. Navitoclax dihydrochloride exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax dihydrochloride can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

ABT-737

77 Cited Publications

Cat. No.: HY-50907

CAS No.: 852808-04-9

Target:

Bcl-2 Family Apoptosis Autophagy Mitophagy

Research Areas:

Inflammation/Immunology Cancer

ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-x_L and Bcl-w inhibitor with EC₅₀s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .

Compare